PBYI

6.9702.11%
TE

Troy Edward Wilson

Independent Director

Dr. Troy Edward Wilson, Ph.D., J.D., serves as Independent Director and Chairman of the Board of Montara Therapeutics, Inc. since March 2025. He is Independent Director of Cartography Biosciences, Inc. from October 2024. Dr. Wilson is Independent Director of Atrium Therapeutics, Inc. since February 2026. He is Co-Founder of Avidity Biosciences Inc. and had been its Executive Chairman since February 2019 until January 2021 and served as its Independent Chairman of the Board since January 2021 until February 27, 2026. Dr. Wilson has been the Chairman of the Board, Chief Executive Officer and President at Kura Oncology, Inc. since March 2015. He was the Chief Financial Officer and Principal Accounting Officer at Kura Oncology, Inc. since July 06, 2018. Dr. Wilson served as President and Chief Executive Officer of Wellspring Biosciences and Araxes Pharma from July 2012 to March 2019. He has served as the sole managing member of Araxes Pharma LLC, since May 2012. Dr. Wilson served as the President and Chief Executive Officer of Avidity Biosciences Inc. (formally known as Avidity Biosciences, Inc.) from November 2012 to February 2019 and serves as its Director since November 2012. He has also served as Executive Chairman of the board of directors of Wellspring Biosciences, Inc., since July 2012. He served as Senior Advisor at Ambrx, Inc. He has been Executive Chairman and a member of the board of directors of Abintus Bio, Inc., a gene therapy company, since October 2020. He served as a Founding Partner CMEA 8 at CMEA Capital. Dr. Wilson joined CMEA Capital in 2012. He served as a Business Advisor of Centrose LLC. He co-founded Wellspring Biosciences. He Co-Founded Intellikine, Inc. and served as its Chief Executive Officer and President from April 2007 to January 2012. He co-founded Ambrx, Inc. in 2003 and served as its Chief Business Officer. He co-founded Wildcat. He served as Vice President of Business Development and General Counsel at the Genomics Institute of the Novartis Research Foundation, where his responsibilities included oversight of all business development, licensing, legal and intellectual property functions of the Institute. He was also actively involved in the creation and launch of the Institute's three spinout companies - Kalypsys, Phenomix and Syrrx. He was associated with a law firm in New York, where he was a Member of its Corporate Finance and Technology transactions practice groups. He has also been a Member of the Board of Managers of Araxes Pharma LLC since May 2012. He served as an Independent Director of Zosano Pharma Corporation since June 20, 2014 until October 5, 2019. He has been a Member of the Board of Managers at Avidity NanoMedicines Inc. since November 2012. He has been a Member of the Board of at Wellspring Biosciences LLC since May 2012. He serves as a Director of Centrose, LLC. Dr. Wilson co-founded Prior Kura in August 2014 and served as the President and Chief Executive Officer of Prior Kura, as well as a member of Prior Kura’s Board of Directors, from August 2014 until the Upstream Merger in March 2015. He has been an Independent Director of Puma Biotechnology, Inc. since October 18, 2013. He served as a Director of Intellikine, Inc. from August 2007 to January 2012. Dr. Wilson is the trustee of Red Fish Blue Fish Revocable Trust. Dr. Wilson holds Ph.D. in Bioorganic Chemistry and a B.A. in Biophysics from the University of California, Berkeley and J.D. from New York University. Dr. Wilson is Director at Abintus Bio Inc. from 2022.

Positions